ALK and non-small cell lung carcinoma: In the phase III CROWN trial, 296 untreated patients with ALK-rearranged advanced NSCLC were randomized to receive lorlatinib at 100 mg once daily (n = 149) or crizotinib at 250 mg twice daily (n = 147) [39].